Product Details
Place of Origin: Chinan
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 115436-72-1
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Aluminum Foil Bag, Drum
Delivery Time: 7-15DAY
Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram
Supply Ability: G,KG,TON
Appearance:: |
Fine White To Off-white Crystalline Powder |
CAS NO:: |
115436-72-1 |
Molecular Formula:: |
C7H10NNaO7P2 |
Molecular Weight:: |
305.09400 |
EINECS NO:: |
658-043-1 |
MDL NO:: |
MFCD01706268 |
Appearance:: |
Fine White To Off-white Crystalline Powder |
CAS NO:: |
115436-72-1 |
Molecular Formula:: |
C7H10NNaO7P2 |
Molecular Weight:: |
305.09400 |
EINECS NO:: |
658-043-1 |
MDL NO:: |
MFCD01706268 |
Product Description:
Product Name: Risedronate Sodium CAS NO: 115436-72-1
Synonyms:
3-Pyridyl-1-hydroxyethylidene-1,1-biphosphonic acid sodium salt;
Phosphonic acid, P,P'-[1-hydroxy-2-(3-pyridinyl)ethylidene]bis-, sodium salt (1:1);
sodium hydrogen-1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethylphosphonate;
Chemical & Physical Properties:
Appearance: Fine white to off-white crystalline powder
Assay :≥98.0%
Boiling Point: 692.3℃ at 760 mmHg
Flash Point: 372.5℃
Vapor Pressure: 4.03E-20mmHg at 25℃
Storage Temp.: Store at RT
Solubility: H2O: soluble5mg/mL, clear (warmed)
Safety Information:
Hazard Declaration: H302 + H312 + H332
Caution Statement: P280
Symbol: GHS07
Signal Word: Warning
Risedronic acid (INN) often used as its sodium salt risedronate sodium (USAN) is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. It is produced and marketed by Warner Chilcott, Sanofi-Aventis, and in Japan by Takeda under the trade names Actonel, Atelvia, and Benet. It is also available in a preparation that includes a calcium carbonate supplement, as Actonel with Calcium. Risedronic Acid is a pyridinyl biphosphonate bone resorption inhibitor. Risedronate sodium is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.Target: Risedronate sodium, which was promoted in Croatia a few months ago, is the latest (III) generation of bisphosphonates, the most efficient anti-resorption drugs that inhibit osteoclast-mediated bone resorption and change the bone metabolism. Risedronate sodium is hence the first line of bisphosphonates for the reduction of vertebral and non-vertebral fracture risks in postmenopausal women with osteoporosis or those with a high risk of osteoporosis.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.